Compare iShares MSCI Hong Kong ETF (EWH) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Humana Inc — how do they compare? iShares MSCI Hong Kong ETF trades at $22.04, while Humana Inc trades at $397.36 (market cap $48.96B). The key difference: Humana Inc pays a 0.87% dividend while iShares MSCI Hong Kong ETF pays none, and Humana Inc is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals.
| EWH | HUM | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $409.42 |
52-Week Low | $20.15 | $163.67 |
Market Cap | — | $48.96B |
Enterprise Value | — | $58.00B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $22.04, up 1.71% with a bullish technical signal from moving averages. The ETF tracks Hong Kong equities, showing recent momentum in Chinese technology stocks as highlighted in recent market coverage. Key resistance and support cluster around $22, while RSI readings suggest potential overbought conditions. The fund declared a $0.35 dividend payable in June 2026.
Outlook remains tied to Hong Kong market performance and Chinese economic factors. Positive catalysts include technology sector rallies and Hong Kong's growing wealth hub status, but risks involve regulatory scrutiny on Chinese brokerages and IPO performance concerns. Investor sentiment is cautiously optimistic amid regional market volatility.
Humana (HUM) trades at $395.78, down 2.68% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 2026 EPS of $10.31, beating expectations, and maintains a P/E of 43.52 and P/S of 0.36. Recent news highlights margin recovery targets and expansion through CenterWell, while investigations into insider sales and cost statements introduce uncertainty.
Outlook is mixed: analyst consensus is $354.33 with 61% hold ratings, reflecting caution despite growth initiatives. Key risks include Medicare Advantage margin pressures and legal scrutiny, but revenue growth to $137.2B in 2026 and a dividend payment in July offer support. Investors should weigh profitability trends against valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
